Partners and Distributors
Pharmaxis selectively partners with pharmaceutical and biotechnology companies to further our clinical endeavours and business aims.
Our partners are:
|In December 2014 Pharmaxis and Chiesi Farmaceutici SpA entered into an exclusive distribution and supply agreement for the commercialisation of Bronchitol® (mannitol) in the United States. Chiesi funded US$22 million of the cost of the phase 3 clinical trial of Bronchitol. Read more. Pharmaxis and Chiesi also have an exclusive distribution and supply agreement for Bronchitol in the United Kingdom, Germany, Ireland (read more), Italy (read more), Norway, Sweden, Finland, Denmark, Cyprus, Spain and Greece.|
|In April 2021 Pharmaxis appointed regional pharma specialty company GEN İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) as its exclusive Bronchitol distributor for Russia. GEN has been the exclusive Bronchitol distributor for Turkey since December 2013. Read more.|
|In August 2015 Pharmaxis and UK biotechnology company Synairgen plc entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2). The collaboration was amended in December 2017. Read more.|
Boehringer Ingelheim acquired the Pharmaxis phase 1 investigational drug PXS-4728 (BI 1467335) in May 2015 and developed it in two indications until September 2020 when Boehringer discontinued the program and returned it to Pharmaxis. The Company received A$83 million from Boehringer over that period and return of its full development program and related data.
Read more here.
In 2023 PXS-4728 will be trialled in isolated Rapid Eye Movement Sleep Behaviour Disorder (iRBD), a precursor to Parkinson’s disease, Parkinson’s UK is providing ~$5m of funding for the study. Read more.
Our global network of distributors provide logistical support services for our approved products in world markets. For more information on our distributors please see: